0001095981NONEfalse00010959812022-10-202022-10-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2022

 

 

PLUS THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-34375	33-0827593
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4200 Marathon Blvd. Suite 200
Austin, Texas				78756
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (737) 255-7194

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		PSTV		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

---

Item 2.02 Results of Operations and Financial Condition.

On October 20, 2022, Plus Therapeutics, Inc. (the “Company”) reported financial results for the quarter ended September 30, 2022 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Number		Description
99.1		Press Release Announcing Financial Results, dated October 20, 2022.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			PLUS THERAPEUTICS, INC.
Date:	October 20, 2022	By:	/s/ Marc H. Hedrick, M.D.
			Marc H. Hedrick, M.D. President and Chief Executive Officer

 

---

 

Exhibit 99.1

 

Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

 

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM)

Completed cGMP manufacturing objectives to support Phase 2 clinical trials for 186RNL

Initiating ReSPECT-GBM Phase 2 trial for recurrent glioblastoma (GBM) in Q4 2022

Management to host conference call today at 5:00 p.m. ET

 

AUSTIN, Texas, October 20, 2022 – Plus Therapeutics, Inc.(Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent business highlights.

 

“The third quarter of 2022 was another period of significant progress for Plus Therapeutics, highlighted by the achievement of three key milestones,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “First, our CPRIT award of $17.6 million substantially funds the LM program through Phase 2 for our lead investigational drug, Rhenium-186 Nanoliposome (186RNL). Second, we moved 186RNL toward a Phase 2 trial for recurrent GBM, which we expect to initiate in the fourth quarter of 2022. Third, we met our timeline for cGMP 186RNL drug availability for all future trials. In addition, the combination of current cash, access to funding, and grant funding, secures our cash runway through 2025.”

 

RECENT HIGHLIGHTS

 

 

---

 

 

THIRD Quarter 2022 FINANCIAL RESULTS

 

UPCOMING EVENTS AND MILESTONES

 

During the remainder of 2022, the Company expects to accomplish the following key business objectives:

 

Third Quarter 2022 Results Conference Call

 

The Company will hold a conference call and live audio webcast at 5:00 p.m. Eastern Time today to discuss its financial results and provide a general business update.

 

A live webcast will be available at ir.plustherapeutics.com/events.

 

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

 

Following the live call, a replay will be available on the Company’s website under the 'For Investor'section. The webcast will be available on the Company’s website for 90 days following the live call.

 

---

 

 

About Plus Therapeutics

 

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

 

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

 

 

---

 

PLUS THERAPEUTICS, INC.

CONSOLIDATED CONDENSED BALANCE SHEETS

(UNAUDITED)

(in thousands, except share and par value data)

 

		September 30, 2022				December 31, 2021
Assets
Current assets:
Cash and cash equivalents		$	20,266			$	18,400
Grant receivable			73				—
Other current assets			540				1,324
Total current assets			20,879				19,724
Property and equipment, net			1,453				1,477
Operating lease right-use-of assets			275				341
Goodwill			372				372
Intangible assets, net			113				51
Other assets			12				16
Total assets		$	23,104			$	21,981
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses		$	5,705			$	4,151
Operating lease liability			107				111
Term loan obligation, current			1,608				1,608
Total current liabilities			7,420				5,870
Noncurrent operating lease liability			172				269
Term loan obligation			4,108				5,005
Warrant liability			—				1
Total liabilities			11,700				11,145
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at September 30, 2022 and December 31, 2021			—				—
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,570,002 and 15,510,025 issued and outstanding at September 30, 2022 and December 31, 2021, respectively			32				16
Additional paid-in capital			472,899				457,730
Accumulated deficit			(461,527	)			(446,910	)
Total stockholders’ equity			11,404				10,836
Total liabilities and stockholders’ equity		$	23,104			$	21,981

 

 

 

---

 

PLUS THERAPEUTICS, INC.

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

(in thousands, except share and per share data)

 

 

 

 

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2022				2021				2022				2021
Grant revenue		$	73			$	—			$	73			$	—
Operating expenses:
Research and development			2,945				1,491				7,560				3,724
General and administrative			2,222				1,990				6,653				4,811
Loss on disposal of property and equipment			—				18				—				18
Total operating expenses			5,167				3,499				14,213				8,553
Operating loss			(5,094	)			(3,499	)			(14,140	)			(8,553	)
Other income (expense):
Interest income			48				5				74				13
Interest expense			(173	)			(232	)			(552	)			(708	)
Change in fair value of liability instruments			—				2				1				4
Total other expense			(125	)			(225	)			(477	)			(691	)
Net loss		$	(5,219	)		$	(3,724	)		$	(14,617	)		$	(9,244	)
Net loss per share, basic and diluted		$	(0.19	)		$	(0.28	)		$	(0.61	)		$	(0.84	)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders			27,441,654				13,264,230				23,789,195				10,961,284

 

 

 

 

---

 

 

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(in thousands)

 

		For the Nine Months Ended September 30,
		2022				2021
Cash flows used in operating activities:
Net loss		$	(14,617	)		$	(9,244	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			460				266
Amortization of deferred financing costs and debt discount			309				417
In process research and development acquired			—				18
Change in fair value of liability instruments			(1	)			(4	)
Stock-based compensation expense			476				425
Non-cash lease expense			(35	)			36
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Grant receivable			73				—
Other current assets			642				12
Accounts payable and accrued expenses			1,955				418
Net cash used in operating activities			(10,738	)			(7,656	)
Cash flows used in investing activities:
Purchases of property and equipment			(381	)			(134	)
Purchase of intangible assets			(117	)
Proceeds from sale of property and equipment			—				50
In process research and development acquired			(250	)			—
Net cash used in investing activities			(748	)			(84	)
Cash flows from financing activities:
Principal payments of long-term obligations			(1,206	)			—
Payment of financing lease liability			—				(8	)
Proceeds from exercise of warrants			—				2,017
Proceeds from sale of common stock, net			14,558				18,665
Net cash provided by financing activities			13,352				20,674
Net increase in cash and cash equivalents			1,866				12,934
Cash and cash equivalents at beginning of period			18,400				8,346
Cash and cash equivalents at end of period		$	20,266			$	21,280
Supplemental disclosure of cash flows information:
Cash paid during period for:
Interest		$	248			$	292
Supplemental schedule of non-cash investing and financing activities:
Unpaid offering cost		$	68			$	139
Right-of-use asset obtained in exchange for lease liabilities		$	—			$	81

 

Investor Contact

Peter Vozzo
ICR Westwicke

(443) 377-4767

Peter.Vozzo@westwicke.com

 

Media Contact

Terri Clevenger

ICR Westwicke

(203) 856-4326

Terri.Clevenger@westwicke.com

 

---